SIETES :: 92261 citas

Resultados de la búsqueda por ENDOCRINOLOGÍA REFINAR BÚSQUEDA

1.

Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102513]

2.

Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking ß-blockers. Mayo Clin Proc 2017;93:409-18. [Ref.ID 102505]

3.

Anónimo. Many lawsuits concerning diabetes drug saxagliptin transferred to US district judge in Kentucky. DIA Daily 2018:5. [Ref.ID 102461]

4.

Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. BIP31.fr 2017;24:60. [Ref.ID 102182]

5.

Anónimo. Semma Therapeutics raises $114 million for new diabetes treatment. DIA Daily 2017:1. [Ref.ID 102151]

6.

Burcu M, Zito JM, Safer DJ, Magder LS, dos-Reis S, Shaya FT, Rosenthal GL. Association of antidepressant medications with incident type 2 diabetes among Medicaid-insured youths. JAMA Pediatrics 2017:16 de octubre. [Ref.ID 102122]

7.

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M, on behalf of the Diabetes Prevention Program(DPP) Research Group. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.. BMJ Open Diabetes Research & Care 2017;5:1-10. [Ref.ID 102101]

8.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]

9.

Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thompson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, for the WHI Investigators. Menopausal Hormone therapy and long-term all-cause and cause-specific mortality. The Women’s Health Initiative randomized trials. JAMA 2017;318:927-38. [Ref.ID 102070]

10.

McNeil M. Menopausal hormone therapy. Understanding long-term risks and benefits. JAMA 2017;318:911-3. [Ref.ID 102069]

11.

Anónimo. Novo Nordisk to pay $58.7 million to settle US probe over diabetes drug liraglutide. DIA Daily 2017:1. [Ref.ID 102045]

12.

Anónimo. FDA rules Novo Nordisk’s diabetes drug reduces risk of heart attack, stroke, cardiovascular death. DIA Daily 2017:2. [Ref.ID 102035]

13.

Gorricho J, Garjón J, Alonso A, Celaya MC, Saiz LC, Erviti J, López A. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case–control study. Br J Clin Pharmacol 2017;83:septiembre. [Ref.ID 102029]

14.

Young LA, Buse JB, Weaver MA, Vu MB, Mitchell M, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE, for the Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings. A randomized trial. JAMA Intern Med 2017;177:920-9. [Ref.ID 102017]

15.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

16.

Driessen JHM, de Vries F, van Onzenoort H, Harvey NC, Neef C, van den Bergh JPW, Vestergaard P, Henry RMA. The use of incretins and fractures – A meta-analysis on population-based real life data. Br J Clin Pharmacol 2017;83:923-6. [Ref.ID 101971]

17.

Sing CW, Wong ICK, Cheung BMY, Chan JCY, Chu JKP, Cheung C-L. Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case–control study. Pharmacoepidemiol Drug Saf 2017;26:248-55. [Ref.ID 101954]

18.

Hampp C, Pippins J. Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiol Drug Saf 2017;26:117-8. [Ref.ID 101950]

19.

Rosich Martí I, Allepuz A, Rodríguez Palomar G, Ortin Font F, Soler Cera M. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. Pharmacoepidemiol Drug Saf 2017;26:91-6. [Ref.ID 101949]

20.

Anónimo. Beta blockers and the risk of CV events in type 2 diabetes. Diabetes in Control 2017:29 de julio. [Ref.ID 101936]